Study S000513

Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Every Two Weeks in Patients with Type 2 Diabetes: a Multicenter, Randomized, Open-Label Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06900075
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 88
Start: 2025-07-30
Primary completion: 2026-01-30
Lead sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:Efsubaglutide Alfa 3mg Q2W and 1mg QW; DRUG:Efsubaglutide Alfa 1mg QW and 3mg Q2W
Results posted: FALSE

Registered primary outcomes

Time in range (TIR) [6-8 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.